Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Equities researchers at Leerink Swann dropped their FY2017 earnings estimates for Sucampo Pharmaceuticals in a research note issued on Friday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of $1.02 for the year, down from their prior forecast of $1.04. Leerink Swann currently has a “Outperform” rating and a $15.00 price target on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $1.81 EPS and FY2021 earnings at $1.93 EPS.

A number of other equities analysts also recently issued reports on the company. Maxim Group reissued a “buy” rating and set a $23.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday. Mizuho reaffirmed a “hold” rating and set a $12.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Zacks Investment Research raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, October 17th. UBS AG dropped their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, October 12th. Finally, BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.50.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2017 Earnings of $1.02 Per Share” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/sucampo-pharmaceuticals-inc-scmp-expected-to-post-fy2017-earnings-of-1-02-per-share/1681701.html.

Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $10.55 on Monday. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.42 and a current ratio of 5.11. The stock has a market capitalization of $491.12, a price-to-earnings ratio of 7.23, a PEG ratio of 2.47 and a beta of 1.38.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the prior year, the company earned $0.30 EPS. The business’s revenue was up 5.9% compared to the same quarter last year.

In other Sucampo Pharmaceuticals news, insider Jason Patrick Meyenburg purchased 4,000 shares of the stock in a transaction on Wednesday, September 6th. The stock was acquired at an average price of $12.13 per share, with a total value of $48,520.00. Following the completion of the acquisition, the insider now owns 30,228 shares in the company, valued at $366,665.64. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of SCMP. Louisiana State Employees Retirement System boosted its holdings in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new stake in Sucampo Pharmaceuticals in the second quarter worth about $116,000. JPMorgan Chase & Co. acquired a new stake in Sucampo Pharmaceuticals in the second quarter worth about $117,000. Karp Capital Management Corp acquired a new stake in Sucampo Pharmaceuticals in the first quarter worth about $119,000. Finally, Pinnacle Associates Ltd. acquired a new stake in Sucampo Pharmaceuticals in the second quarter worth about $122,000. 55.54% of the stock is owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.